Prevalence of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD+) in de novo acute myeloid leukemia patients categorized according to cytogenetic risk

Krum, Everson Augusto; Yamamoto, Masahiro; Chauffaille, Maria de Lourdes Lopes Ferrari

doi:10.1590/s1516-31802009000100006

Cited by 3 publications

(1 citation statement)

References 19 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The one-year survival rate of AML patients with FLT3-ITD mutation is lower than patients without the mutation. [9][10][11][12] Another factor that affects prognosis of AML patients is plasma FLT3 plasma ligand level. FLT3 mutant receptor which activates proliferation in leukemic cells is shown to be hyperresponsive towards FLT3 ligand.…”

Section: Introductionmentioning

confidence: 99%

FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients

Rinaldi

Louisa

Sari

et al. 2021

OTT

View full text Add to dashboard Cite

Objective To analyze the association of FLT3-ITD mutation and FLT3 ligand plasma level with one-year survival of Indonesian acute myeloid leukemia (AML) patients. Methods A prospective cohort study was conducted to determine the association between FLT-3-ITD mutation and FLT3 ligand plasma level with one-year survival of Indonesian AML patients. In the study, a total of 51 AML patients were obtained from two tertiary hospitals in Indonesia from year 2018 to 2020. Inclusion criteria were de novo AML male and female patients aged ≥18 years old. Exclusion criteria were prior myelodysplastic syndrome and patients that refused to participate in the study. FLT3-ITD genotype of patients was then analyzed using PCR method while FLT3 ligand plasma level was measured using ELISA method. Patients were then followed-up for 1 year or until death occurred with survival as the measured outcome. Association between independent and dependent variable were analyzed by cox regression proportional hazard. Results Eleven patients (21.5%) in this study had FLT3-ITD mutation. The median age of AML patients was 45 (18–71) years, and the median blast percentage was 50% (5–87%). After one-year follow-up, 33 (64.7%) patients had died. The median survival of AML patients was 6 months. Univariate analysis showed no association between FLT3-ITD mutation status (HR: 1.051 ; 95% CI: 0.483–2.286; P: 0.901) and FLT3 ligand plasma level (HR: 0.798; 95% CI: 0.347–1.837; p= 0.596), and age (HR: 1.283; 95% CI: 0.575–2.862; p= 0.542) with one-year survival of AML patients, but multivariate analysis showed association between GFR with one-year survival of AML patients in this cohort (HR: 4.053; 95% CI: 1.469–11.183; p= 0.007). Conclusion One-year survival of AML patients in Indonesia is not affected by FLT3-ITD mutation and FLT3 ligand plasma level. However, GFR showed association with one-year survival of AML patient in this cohort study.

show abstract

Section: Introductionmentioning

confidence: 99%